Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer.
After 27.7 months of follow-up in the phase III NATALEE trial, the invasive disease-free survival benefit with Kisqali (ribociclib) plus endocrine therapy was consistent across key prespecified subgroups, compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC).
In the phase III PSMAfore trial, Pluvicto (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer after treatment with androgen receptor pathway inhibitor therapy, compared to a change in ARPI1.
In the phase III ALINA study, Alecensa (alectinib) reduced the risk of disease recurrence or death by 76% (hazard ratio [HR]=0.24, 95% CI: 0.13-0.43, p<0.0001) compared with platinum-based chemotherapy in people with completely resected stage 1B (tumor ≥4 cm) to 3A (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
Recently diagnosed cancer patients often decide on their own to visit hospital emergency departments for symptoms that don’t warrant that type of care, UT Southwestern Medical Center researchers report.
A study published in Journal of Personalized Medicine explores how oncology subspecialist reviews of pancreatic adenocarcinoma cases can identify care gaps and provide recommendations intended to improve treatment outcomes.
A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant Keytruda (pembrolizumab).
Results from the phase II TRUST-II trial demonstrate that taletrectinib, an investigational next-generation ROS1 inhibitor, shrank tumors (confirmed objective response rate, cORR, as assessed by an independent review committee, IRC) in 92% of patients with advanced ROS1-positive non-small cell lung cancer who had not previously been treated with a ROS1 tyrosine kinase inhibitor.
A study demonstrated that viral immune evasion enabled breakthrough infections of COVID-19 in patients with lung cancer, highlighting the importance of effective monitoring mechanisms, such as anti-N serology, to track infection rates in specific vulnerable populations.